EORTC supports World Cancer Day 2015
2 Feb 2015
Cancer knows no boundaries. It has, or will, affect us all, directly or indirectly, during our lifetime. In the face of this disease and its consequences, World Cancer Day was organized to raise awareness of the disease and press governments and individuals across the world to take action.
Tremendous progress has been made in the last 50 years with significant increases in survival. New breakthroughs in molecular biology are allowing us to progress further and target treatments according to the characteristics of tumors. The EORTC, too, has launched a major research program, SPECTA (Screening Patients for Efficient Clinical Trial Access), with the aim of further developing personalized medicines.
Wednesday, 04 February 2015 marks World Cancer Day 2015, and on this day the EORTC, with its long history of improving treatments for patients with cancer, joins the Union for International Cancer Control (UICC), its members, partners, supporters and the entire world in the fight against the global cancer epidemic and promoting cancer awareness.
The EORTC is committed to improving treatments for patients with cancer and improving the quality of life for cancer patients and also, importantly, cancer survivors. In this spirit, the EORTC has organized:
- A session at European Business Summit 2015, 06-07 May 2015 in Brussels, to address Cancer and Employment. Here, Marianne Thyssen, EU Commissioner of Employment, Social Affairs, Skills and Labor Mobility will present a keynote lecture.
- Innovation and Biomarkers in Cancer Drug Development, IBCD 2015, a first of its kind joint meeting by the EORTC, along with the US National Cancer Institute, the European Medicines Agency, and the American Association for Cancer Research on 3-4 December 2015 at the Square Brussels Meeting Centre. IBCD will shine a spotlight on multi-stakeholder approaches to cancer drug development with new cancer biomarkers in a scientific program which will include input from regulators, industry, and academia.
- 2nd EORTC Cancer Survivorship Summit, 31 March – 01 April 2016 in Brussels, because we need to address not just problems such as late toxicity and secondary tumors, generally viewed as the domain of medical professionals, but also the wide variety of societally significant issues related to jobs, life insurance, mortgages, etc.
These EORTC events are essential in forging the required partnerships to bring about improvements for all of us, those affected by the impact of cancer. Cancer can have a serious impact on a person’s emotional, physical and mental state and cancer survivors are at risk of diminished quality of life for many years following their diagnosis. The EORTC is committed not just to improving treatments, but also to addressing the myriad problems facing cancer patients and cancer survivors in their daily lives.
John Bean, PhD
EORTC, Medical Science Writer
Related News
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
